- Home
- / Opiant Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Opiant Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$20.6
2023-03-02
Market Capitalization
$108.8 M
2023-03-02
Revenue
$47.8 M
FY, 2021
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|---|
| Revenue | 18.4M | 14.0M | 40.5M | 29.6M | 47.8M |
| Revenue growth, % | -24.2% | ||||
| Gross profit | 40.5M | ||||
| Gross profit margin, % | 100.0% | ||||
| General and administrative expense | 6.5M | 11.3M | 12.2M | 11.7M | 12.2M |
| Operating expense total | 11.4M | 35.2M | 29.6M | 25.7M | |
| EBIT | 7.1M | (21.2M) | 10.9M | (2.2M) | 5.2M |
| EBIT margin, % | 38.5% | -151.6% | 26.9% | -7.6% | |
| Interest income | 20.0K | 144.7K | |||
| Interest expense | 20.0K | 437.7K | |||
| Pre tax profit | 7.1M | (21.1M) | 11.4M | (2.3M) | 3.0M |
| Income tax expense | 550.5K | 51.3K | (177.2K) | (425.7K) | 24.3K |
| Net Income | 6.6M | (21.2M) | 11.6M | (1.9M) | 3.0M |